ClinicalTrials.gg
Drug

Abrocitinib clinical trials

Also written PF-04965842 and CIBINQO.

studies test it
42
open now
6
in phase 3
11
first study started
2013

How each study uses abrocitinib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the abrocitinib studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
14 Jan 2022 · CIBINQO · NDA 213871 (FDA, Drugs@FDA)
European Union
9 Dec 2021 · Cibinqo · EMEA/H/C/005452 (EMA)

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Abrocitinib
13
Abrocitinib 200 mg
6
PF-04965842 200 mg
5
PF-04965842 100 mg
5
Abrocitinib 100 mg
2

Brand

CIBINQO
3

Development codes

PF-04965842
19

Studies by the year they started

41 studies that test it; most in 2018 (12); 1 more planned to start later

Studies that test abrocitinib, by start year
YearStudies
20131
20142
20161
20172
201812
20194
20202
20213
20223
20234
20242
20252
20263

By phase

A phase 1/2 study counts in both.

Early Phase 1
1
Phase 1
17
Phase 2
10
Phase 3
11
Phase 4
3

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 30 · Other 12

Pfizer (30) · Innovaderm Research Inc. (2) · Icahn School of Medicine at Mount Sinai (2) · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (1) · Beth Israel Deaconess Medical Center (1) · William Damsky (1) · Yale University (1) · Johns Hopkins University (1)

Often tested with

Tested in the same studies.

Tofacitinib (2) · PF-06651600 (1) · Ethinyl Estradiol (1) · Levonorgestrel (1) · Triamcinolone (1) · Fluorouracil (1) · Calcipotriene (1) · Tapinarof (1)

Related medicines

As reviewed, each with the page that says it.

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Reaching primary completion within a year · 2, 1 in phase 3

Studies that test abrocitinib, phase 3 first.

Studies

Open first, then newest update. How each study uses abrocitinib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 42

See all 42 studies that test abrocitinib →

Given beside what is tested · 1 — abrocitinib is usual care or a partner of the new treatment

Codes

What other systems call abrocitinib · ClinicalTrials.gg INT001172

  • MeSH (NLM) C000634427abrocitinibConfirmed ClinicalTrials.gov, NLM
  • UNII (FDA) 73SM5SF3ORABROCITINIBConfirmed FDA, NLM
  • RxNorm 2591476One source FDA
  • NCI Thesaurus C166985AbrocitinibOne source FDA

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.